Skip to main content
Fig. 7 | Biomaterials Research

Fig. 7

From: Controlled release of Clenbuterol from a hydroxyapatite carrier for the treatment of Alzheimer’s Disease

Fig. 7

Pharmacokinetic profiles illustrating the mean plasma concentration-time curves of CLB following intramuscular administration of free CLB and SHAP-CLB carrier were examined. Representative LC-MS/MS chromatograms, including (A) blank plasma spiked with CLB and IS, and (B) LC-MS/MS mobile phase gradient elution condition, are shown. (C) The mean plasma concentration-time curves of CLB and SHAP-CLB after intramuscular administration of CLB (6 mg/kg) alone and the carrier of CLB (6 mg/kg). The mean drug plasma concentration-time curves of CLB and SHAP-CLB after intramuscular administration of CLB and drug carriers at a dose of 6 mg/kg are illustrated in (D) and (E), respectively (data represent the mean ± standard deviation values, n = 6)

Back to article page

Biomaterials Research

ISSN: 2055-7124

Contact us